Activin A is a member of the TGF-β superfamily and activates the transcription factors 7 SMAD2/3 through the ALK4 type 1 receptor. Activin A has also been shown to activate 8 SMAD1/5/8 through mutated variants of the type 1 receptor ALK2. Interestingly, we here show 9 that both activin A and activin B could activate SMAD1/5/8 through endogenous wild type 10 ALK2 in multiple myeloma cells. Knockdown of the type 2 receptor BMPR2 strongly 11 potentiated activin A-and activin B-induced SMAD1/5/8 activation and subsequent cell death.
Introduction
for myeloma cell survival (Holien and Sundan, 2014; Holien et al., 2012a; Holien et al., 2012b) . 23 Ligands that activate the SMAD2/3-, but not the SMAD1/5/8-pathway, such as TGF-β, do not 24 induce apoptosis in myeloma cells (Baughn et al., 2009; Olsen et al., 2015) . We and others have 25 shown that activin A may compete with BMPs for binding to ACVR2A, ACVR2B and ALK2 Piek et al., 1999; Seher et al., 2017) . Activin A could also induce a weak phosphorylation of 28 SMAD1/5/8 in addition to the canonical activation of SMAD2 (Olsen et al., 2015) . This 29 coincided with a modest reduction in myeloma cell viability. Interestingly, it was shown that 30 activin A bind and signal through a mutated variant of ALK2, encoded by ACVR1 R206H 31 (Hatsell et al., 2015; Hino et al., 2015) . 32 In this study, we wanted to clarify how activins may affect myeloma cell survival. We 33 found that both activin A and activin B signaled through endogenous levels of wild type ALK2 to phosphorylate the BMP-activated SMADs, SMAD1 and SMAD5, and consequently induced 1 myeloma cell death. Surprisingly, depletion of BMPR2 strongly augmented ALK2-, but not 2 ALK4-mediated signaling, induced by either activins or BMPs. In conclusion, we propose that 3 BMPR2 prevents ALK2 from forming active receptor signaling complexes with ACVR2A and 4 ACVR2B, thus inhibiting ALK2-mediated SMAD1/5/8-activation and myeloma cell death. 5 
Results

1
Activin A and activin B inhibited myeloma cells through ALK2 and SMAD1/5/8 2 Five different myeloma cell lines were treated with increasing doses of activin A or activin B 3 for three days. A dose-dependent decrease in relative viable cell numbers was seen in IH-1 and 4 to a lesser extent in the INA-6 cell line (Fig.1A,B) . The other three cell lines were for a large 5 part refractory to activin A-or activin B-induced growth inhibition in the doses used here. 6 Notably, both activins induced canonical activation of SMAD2 in all cell lines, whereas a clear 7 activation of SMAD1/5/8 was also observed in the IH-1, INA-6 and KJON cell lines (Fig. 1C ). 8 Contamination by other ligands is a potential issue when using recombinant proteins (Carthy et 9 al., 2016; Olsen et al., 2017) . Thus, to confirm that the observed effects were actually caused 10 by activin A and activin B, we performed experiments on SMAD-activity in the presence of 11 neutralizing antibodies ( Fig. S1 ). As shown, antibodies towards activin A and activin B reduced 12 activin A-and activin B-induced SMAD1/5/8 phosphorylation to background levels, indicating 13 that the observed SMAD1/5/8 phosphorylation indeed was due to activin A and activin B and 14 not to contamination factors. We and others have previously shown that activation of 15 SMAD1/5/8, but not SMAD2, induced growth arrest or apoptosis in human myeloma cells 16 (Baughn et al., 2009; Holien et al., 2012a; Olsen et al., 2015) . In line with this, we also here 17 show that activin A and activin B induced apoptosis in IH-1 cells as measured by annexin V 18 labeling and cleavage of caspase 3 (Fig. 1D,E) . Activin A has previously been shown to signal 19 through ALK4 whereas activin B bind and signal through either ALK4 or ALK7 (Wakefield 20 and Hill, 2013). Neither ALK4 nor ALK7 are thought to activate SMAD1/5/8. Thus, the results 21 above suggest that activin A and activin B also may bind and signal through complexes 22 containing BMP-type 1 receptors. 23 
24
Activins signaled through endogenous wild type ALK2 in myeloma cells 25 To clarify which BMP-type 1 receptor could be responsible for activin-induced activation of 26 SMAD1/5/8, we first measured the mRNA levels of the potential TGF-β superfamily receptors 27 ( Fig. 2A ). ALK1/ACVRL1 and ALK6/BMPR1B were also measured, but omitted in the figure 28 since none of the cell lines showed expression of these two receptors. Since the only BMP-type 29 1 receptor expressed in INA-6 cells was ALK2, whereas IH-1 cells expressed both ALK2 and 30 ALK3, ALK2 was the likely responsible type 1 receptor present in both cell lines. We then 31 employed DMH1 and K02288, inhibitors of SMAD1/5/8-activation, to see their effects on 32 apoptosis induced by activin A and activin B. DMH1 targets BMP-activated ALKs selectively, 33 whereas K02288 has been described as an inhibitor that targets ALK2 more potently than the other BMP-activated ALKs (Hao et al., 2010; Sanvitale et al., 2013) . Both inhibitors 1 significantly inhibited the reduction in cell viability caused by activin A and activin B ( Fig.   2 2B,C). We then compared these results with inhibition of ALK4/5/7 by using the SB431542 3 inhibitor (Inman et al., 2002) . This inhibitor showed no significant effect on activin A-induced 4 apoptosis and a modest, but significant effect on activin B-induced apoptosis (Fig. 2D ). To 5 target ALK2 even more specifically, we utilized a novel, monoclonal ALK2 neutralizing 6 antibody termed DaVinci (Katagiri et al., 2017) . The antibody blunted apoptosis induced by 7 activin A and activin B, as well as by BMP9, which we have previously shown to use ALK2 to 8 activate the SMAD1/5/8-pathway in these cells (Olsen et al., 2014) . Taken together, the results 9 support that ALK2 is the BMP-type 1 receptor for activin A and activin B in these cells. Of 10 note, whole exome sequencing of 69 human myeloma cell lines, including INA-6, did not reveal 11 any mutations in ALK2 (data not shown; publicly available data from the Keats lab website; 12 http://www.keatslab.org/data-repository). We also RNA-sequenced our own batch of INA-6 13 cells. Two single nucleotide variations (SNVs) were detected in the ALK2 gene, ACVR1, 14 denoted rs2227861 and rs1146031, none of which cause a change in the amino acid sequence 15 (data not shown). Thus, this we here report for the first time that, not only activin B, but also 16 activin A, can signal through endogenous levels of wild type ALK2. 17 18 Loss of BMPR2 potentiated activin-induced SMAD1/5/8 activity 19 ACVR2A and ACVR2B are known type 2 receptors for activins and BMPs. Also, BMPR2 is 20 an important BMP type 2 receptor, but the role for BMPR2 in activin-mediated signaling is less 21 clear. We thus generated cells with stable expression of shRNA targeting BMPR2 (shBMPR2), 22 using as controls non-targeting shRNA (shCTR) or shRNA targeting ACVRL1 (shALK1), 23 which is not expressed by myeloma cell lines. Expression of BMPR2 mRNA was measured in 24 shRNA-expressing cells and indicated a reduction to approximately 10 % and 40 % compared 25 to the levels in control-transduced INA-6 and IH-1 cells, respectively ( Fig. 3A,B ). BMPR2 26 protein levels could be detected by immunoblotting in INA-6 cells and there was a clear 27 downregulation of BMPR2 in the shBMPR2-cells compared with control cells (Fig. S2 ). In IH- 28 1 cells we were not able to detect BMPR2 protein clearly, and thus, we could not determine the 29 degree of downregulation at the protein level. Importantly, activin A activated SMAD1/5/8 30 more strongly in cells where BMPR2 was downregulated than in control cells, whereas activin 31 A-induced activation of SMAD2 in the same cells was not affected by BMPR2 knockdown 32 ( Fig. 3C,D) . Also, the mRNA levels of ID1, a known SMAD1/5/8 target gene,(Chen et al., To investigate if the effects of BMPR2 expression levels on BMP-and activin-induced 20 activation of SMAD1/5/8 signaling also could be seen in other cells, we transiently transfected 21 HepG2 liver carcinoma cells with siRNA targeting BMPR2 (siBMPR2) or non-targeting siRNA 22 (siCTR). The cells were treated for four hours with BMP6, activin A or activin B (all at a 23 concentration of 10 ng/mL) and activation of SMADs was determined by immunoblotting.
Interestingly, also in HepG2 cells activation of SMAD1/5/8 by these ligands was potentiated 25 by BMPR2 knockdown, whereas activation of SMAD2 remained unaffected (Fig. 5A ). The 26 mRNA expression of the SMAD target gene ID1 in activin A-treated HepG2 cells after BMPR2 27 knockdown was also augmented (Fig. 5B ). The levels of BMPR2 mRNA in these experiments 28 were reduced to < 20 % of mRNA levels in control cells (Fig. 5C ). In summary, also in HepG2 The aim of this study was to clarify how activins affected myeloma cell survival. We earlier 2 found that activin A could inhibit BMP6-and BMP9-signaling through ALK2 (Olsen et al., SMAD2 pathway has not been found to induce apoptosis, whereas we earlier found that 7 activation of the SMAD1/5/8-pathway was necessary and sufficient for induction of apoptosis. 8 The most important finding presented here is that activin A and activin B activated the non- manuscript, there was also a report describing that activin A could induce SMAD1/5/8-activity 20 through overexpressed wild type ALK2, strongly supporting our findings (Haupt et al., 2017). 21 Activin B has been shown to activate SMAD1/5/8 in hepatocytes through ALK2, ACVR2A 22 and ACVR2B (Besson-Fournier et al., 2012; Canali et al., 2016). In line with these results, we 23 here show that both activin A and activin B are able to activate SMAD1/5/8 through the 24 endogenous wild type ALK2 receptor in myeloma cells, leading to cell death. 25 
26
Activin A-induced SMAD1/5/8-activation and consequently myeloma cell death was strongly 27 augmented when levels of BMPR2 were reduced. Furthermore, the effects of activin B, BMP6, 28 BMP7 and BMP9, which also utilize ALK2 as type 1 receptor, were potentiated in the same 29 way. Our results resemble previously described effects in human mesenchymal stem cells, 30 where BMP2 and BMP4 preferred BMPR2 over ACVR2, whereas BMP6 and BMP7 preferred 
33
In pulmonary artery smooth muscle cells (PASMC) loss of BMPR2 augmented signaling by BMP6 and BMP7, whereas BMP2 and BMP4 signaling was diminished (Yu et al., 2005) . 1 Contrary to the report on PASMC, we observed no change in the activity of BMP2 or BMP4. 2 We speculate that this may be due to compensatory utilization of the type 2 receptors ACVR2A 3 and ACVR2B by BMP2 and BMP4 in the cell types used here. The same might apply for 4 BMP10-induced growth inhibition, which was also not changed in cells with lower levels of 5 BMPR2. On the other hand, another study found that deleting Bmpr2 in mouse skeletal 6 progenitor cells selectively impaired activin A-induced SMAD2/3 activation, but had no effect 7 on BMP signaling, causing increased bone formation and bone mass (Lowery et al., 2015) . We 8 did not see any significant difference in activin A-or activin B-induced activation of SMAD2 9 in myeloma cells by lowering BMPR2 levels. The differences between our study and the 10 previously reported results may be due to variations in cellular receptor expression. A possible mechanism for the potentiating effects of activin A seen after knocking down 23 BMPR2, could be that activin A bind ALK2-BMPR2 or ALK2-ACVR2 equally well, but 24 induce a weaker signal through ALK2-BMPR2. However, cross-linking experiments with 25 radioactive activin A showed binding of activin A to ALK2 when the receptor was co-expressed 26 with ACVR2A or ACVR2B, but not with BMPR2 (Hino et al., 2015). Another study found that 27 overexpression of Müllerian inhibiting substance receptor II (MISRII) could sequester ALK2. 28 Activin A signaling through ALK4 was thereby potentiated suggesting that presence of ALK2 2007). The latter study also showed that ALK2 could bind ACVR2A in the absence of ligand. 31 Both studies support our hypothesis that BMPR2 might sequester ALK2 and prevent complex 32 formation between ALK2 and ACVR2A or ACVR2B. A proposed model of our hypothesis is 33 provided (Fig. 6 ). BMPs and activins can be targeted clinically by use of soluble decoy receptors (for a recent 16 review, see (Lowery et al., 2016) ). This approach is based on the ligands' affinities to receptor 17 and may not be a specific way of targeting a particular signaling pathway. In attempts to treat 18 multiple myeloma, it may be better to increase the BMP activity specifically in the cancerous 19 cells. Our results indicate that one way of doing this could be by reducing the levels of BMPR2. 20 To conclude, we hypothesize that reducing the levels of BMPR2 enables increased formation 21 of endogenous receptor complexes of ALK2 with ACVR2A or ACVR2B. The BMPR2-levels 22 could thus dictate the degree of SMAD1/5/8-activation by activin A, activin B and several 23 BMPs. Increased BMPR2 expression in myeloma cells could therefore be one way of escaping 24 the tumor suppressive effects of activins and BMPs. Thus, lowering BMPR2 levels in myeloma 25 cells may be beneficial; but this issue needs to be investigated further. To measure changes in cell viability, cells were stained using Apotest FITC kit (Nexins 2 Research, Kattendijke, The Netherlands). In brief, cells were incubated with annexin V FITC 3 (0.2 µg/ mL in 1X binding buffer) for one hour on ice. Propidium iodide (PI) (1.4 µg/mL) was 4 added five minutes prior to data acquisition using an LSRII flow cytometer (BD Biosciences, 5 San Jose, CA). Cells negative for both annexin V and PI staining were considered viable. 6 7 Generation of shRNA-expressing cell lines 8 ShRNA constructs were purchased as ready-made lentiviral particles and consisted of pools of 9 three different sequences targeting BMPR2 (sc-40220-V) or ALK1 (sc-40212-V), and non-10 targeting control shRNA (sc-108080) (Santa Cruz Biotechnology, Inc., Heidelberg, Germany). Thermo Fisher Scientific) as described previously (Olsen et al., 2015) . The Taqman assays used were treated with increasing doses of BMP6, BMP9, BMP2, BMP4 or BMP10 for three days 7 and the relative cell numbers were determined by the CellTiter Glo assay. Shown are 8 representative experiments of at least three independent experiments with mean±s.d. of n=3 9 technical replicates. RLU; relative luminescence units. 3 In the dotted-line box to the left the possible combinations of ALK2 with a type 2 receptor are 4 shown. Yellow arrows suggest receptor-complex preference. If ALK2 is a limiting factor, the 5 preference for complex formation with a given type 2 receptor will determine signaling 6 outcome. Thus, when levels of BMPR2 are lowered, more ALK2 may be available for complex 7 formation with ACVR2A or ACVR2B, necessary for proper ALK2-signaling by the ligands 8 activin A, activin B, BMP6, BMP7, or BMP9. 
